J Liu1, Y Y Li2, A K Andiappan3, Y Yan1, K S Tan1, H H Ong1, K T Thong4, Y K Ong4, F G Yu1, H B Low5, Y L Zhang5, L Shi6, D Y Wang1. 1. Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. 2. Department of Biomedical Engineering, National University of Singapore, Singapore, Singapore. 3. Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A*STAR), Singapore, Singapore. 4. Department of Otolaryngology-Head and Neck Surgery, National University Health System (NUHS), Singapore, Singapore. 5. Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. 6. Department of Otolaryngology, The Second Hospital of Shandong University, Jinan, China.
Abstract
BACKGROUND: The IL-13 receptor α2 (IL-13Rα2) is a receptor for IL-13 which has conflicting roles in mediating IL-13 responses in the lower airway, with little known about its impact on upper airway diseases. We sought to investigate the expression of IL-13 receptors, IL-13Rα1 and IL-13Rα2, in chronically inflamed nasal epithelium, and explore IL-13-induced signaling pathways in an in vitro model of human nasal epithelial cells (hNECs). METHODS: The protein and mRNA expression levels of IL-13 and its receptors in nasal biopsies of patients with nasal polyps (NP) and healthy controls were evaluated. We investigated goblet cell stimulation with mucus hypersecretion induced by IL-13 (10 ng/mL, 72 hours) treatment in hNECs using a pseudostratified epithelium in air-liquid interface (ALI) culture. RESULTS: There were significant increases in IL-13, IL-13Rα1, and IL-13Rα2 mRNA and protein levels in NP epithelium with healthy controls as baseline. MUC5AC mRNA positively correlated with IL-13Rα2 (r = .5886, P = .002) but not with IL-13Rα1 in primary hNECs. IL-13 treatment resulted in a significant increase in mRNA and protein levels of IL-13Rα2 only in hNECs. IL-13 treatment induced an activation of extracellular signal-regulated kinases (ERK)1/2 and an upregulation of C-JUN, where the IL-13-induced effects on hNECs could be attenuated by ERK1/2 inhibitor (50 μmol/L) or dexamethasone (10-4 -10-7 mol/L) treatment. CONCLUSIONS: IL-13Rα2 has a potential role in IL-13-induced MUC5AC and ciliary changes through ERK1/2 signal pathway in the nasal epithelium. IL-13Rα2 may contribute to airway inflammation and aberrant remodeling which are the main pathological features of CRSwNP.
BACKGROUND: The IL-13 receptor α2 (IL-13Rα2) is a receptor for IL-13 which has conflicting roles in mediating IL-13 responses in the lower airway, with little known about its impact on upper airway diseases. We sought to investigate the expression of IL-13 receptors, IL-13Rα1 and IL-13Rα2, in chronically inflamed nasal epithelium, and explore IL-13-induced signaling pathways in an in vitro model of human nasal epithelial cells (hNECs). METHODS: The protein and mRNA expression levels of IL-13 and its receptors in nasal biopsies of patients with nasal polyps (NP) and healthy controls were evaluated. We investigated goblet cell stimulation with mucus hypersecretion induced by IL-13 (10 ng/mL, 72 hours) treatment in hNECs using a pseudostratified epithelium in air-liquid interface (ALI) culture. RESULTS: There were significant increases in IL-13, IL-13Rα1, and IL-13Rα2 mRNA and protein levels in NP epithelium with healthy controls as baseline. MUC5AC mRNA positively correlated with IL-13Rα2 (r = .5886, P = .002) but not with IL-13Rα1 in primary hNECs. IL-13 treatment resulted in a significant increase in mRNA and protein levels of IL-13Rα2 only in hNECs. IL-13 treatment induced an activation of extracellular signal-regulated kinases (ERK)1/2 and an upregulation of C-JUN, where the IL-13-induced effects on hNECs could be attenuated by ERK1/2 inhibitor (50 μmol/L) or dexamethasone (10-4 -10-7 mol/L) treatment. CONCLUSIONS: IL-13Rα2 has a potential role in IL-13-induced MUC5AC and ciliary changes through ERK1/2 signal pathway in the nasal epithelium. IL-13Rα2 may contribute to airway inflammation and aberrant remodeling which are the main pathological features of CRSwNP.
Authors: Niccolette Schaefer; Xingnan Li; Max A Seibold; Nizar N Jarjour; Loren C Denlinger; Mario Castro; Andrea M Coverstone; W Gerald Teague; Jonathan Boomer; Eugene R Bleecker; Deborah A Meyers; Wendy C Moore; Gregory A Hawkins; John Fahy; Brenda R Phillips; David T Mauger; Azzeddine Dakhama; Shaan Gellatly; Nicole Pavelka; Reena Berman; Y Peter Di; Sally E Wenzel; Hong Wei Chu Journal: JCI Insight Date: 2019-04-18
Authors: Yanyi Tu; Jing Liu; Tao Li; Xiangmin Zhou; Kai Sen Tan; Hsiao Hui Ong; Kaiyue Sun; Yi Ouyang; Xu Liang; Yew Kwang Ong; Mark Thong; Li Shi; De-Yun Wang Journal: Inflammation Date: 2021-05-17 Impact factor: 4.092
Authors: Kai Sen Tan; Anand Kumar Andiappan; Bernett Lee; Yan Yan; Jing Liu; See Aik Tang; Josephine Lum; Ting Ting He; Yew Kwang Ong; Mark Thong; Hui Fang Lim; Hyung Won Choi; Olaf Rotzschke; Vincent T Chow; De Yun Wang Journal: Cells Date: 2019-08-27 Impact factor: 6.600
Authors: Qianmin Chen; Kai Sen Tan; Jing Liu; Hsiao Hui Ong; Suizi Zhou; Hongming Huang; Hailing Chen; Yew Kwang Ong; Mark Thong; Vincent T Chow; Qianhui Qiu; De-Yun Wang Journal: Front Cell Dev Biol Date: 2020-12-21
Authors: Yannick van Sleen; William F Jiemy; Sarah Pringle; Kornelis S M van der Geest; Wayel H Abdulahad; Maria Sandovici; Elisabeth Brouwer; Peter Heeringa; Annemieke M H Boots Journal: Arthritis Rheumatol Date: 2021-11-01 Impact factor: 15.483